@article{Lesmes-Rodriguez2023,
abstract = {Background: Globally, the most significant risk factors for adverse COVID-19 outcome are increasing age and cardiometabolic comorbidities. However, underlying coinfections may modulate COVID-19 morbidity and mortality, particularly in regions with high prevalence of infectious diseases. Methods: We retrospectively analyzed serum samples for IgG antibodies against the common circulating coronaviruses HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1 from non-hospitalized and hospitalized confirmed COVID-19 patients recruited during the first (June-August 2020) and second (October 2020-June 2021) COVID-19 wave in Cape Town, South Africa. Patients were grouped according to COVID-19 disease severity: Group 1: previously SARS-CoV-2 infected with positive serology and no symptoms (n=94); Group 2: acutely SARS-CoV-2 infected, hospitalized for COVID-19 and severe symptoms (n=92). Results: The overall anti-HCoV IgG seroprevalence in the entire patient cohort was 60.8{\%} (95{\%} CI: 53.7 – 67.8), with 37.1{\%} HCoV-NL63 (95{\%} CI: 30 – 44), 30.6{\%} HCoV-229E (95{\%} CI: 24 – 37.3), 22.6{\%} HCoV-HKU1 (95{\%} CI: 16.6 – 28.6), and 21.0{\%} HCoV-OC43 (95{\%} CI: 15.1 – 26.8). We observed a significantly higher overall HCoV presence (72.3{\%} versus 48.9{\%}) and coinfection frequency (43.6{\%} versus 19.6{\%}) in group 1 compared to group 2 patients with significantly higher presentation of HCoV-NL63 (67.0{\%} versus 6.6{\%}) and HCoV-HKU1 (31.1{\%} versus 14.1{\%}). However, only antibody titers for HCoV-NL63 were significantly higher in group 1 compared to group 2 patients (p {\textless} 0.0001, 1.90 [95{\%} CI: 0.62 – 2.45] versus 1.32 [95{\%} CI: 0.30 – 2.01]) which was independent of the participants' HIV status. Logistic regression analysis revealed significantly protective effects by previous exposure to HCoV-NL63 [p {\textless} 0.001, adjusted OR = 0.0176 (95{\%} CI: 0.0039 – 0.0786)], while previous HCoV-229E exposure was associated with increased COVID-19 severity [p = 0.0051, adjusted OR = 7.3239 (95{\%} CI: 1.8195–29.4800)]. Conclusion: We conclude that previous exposure to multiple common coronaviruses, and particularly HCoV-NL63, might protect against severe COVID-19, while no previous HCoV exposure or single infection with HCoV-229E might enhance the risk for severe COVID-19. To our knowledge, this is the first report on HCoV seroprevalence in South Africa and its possible association with cross-protection against COVID-19 severity.},
author = {Lesmes-Rodr{\'{i}}guez, Lida C and Lambarey, Humaira and Chetram, Abeen and Riou, Catherine and Wilkinson, Robert J and Joyimbana, Wendy and Jennings, Lauren and Orrell, Catherine and Jaramillo-Hern{\'{a}}ndez, Dumar A and Sch{\"{a}}fer, Georgia},
doi = {10.3389/FVIRO.2023.1125448/BIBTEX},
issn = {2673818X},
journal = {Frontiers in Virology},
keywords = {COVID-19,HCoV-229E,HCoV-HKU1,HCoV-NL63,HCoV-OC43,OA,SARS-CoV-2,Serology,fund{\_}ack,genomics{\_}fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,genomics{\_}fund{\_}ack,original},
month = {feb},
pages = {1125448},
publisher = {Frontiers Media SA},
title = {{Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa}},
volume = {3},
year = {2023}
}

{"_id":"w5CwCb93e8jEPCzDc","bibbaseid":"lesmesrodriguez-lambarey-chetram-riou-wilkinson-joyimbana-jennings-orrell-etal-previousexposuretocommoncoronavirushcovnl63isassociatedwithreducedcovid19severityinpatientsfromcapetownsouthafrica-2023","author_short":["Lesmes-Rodríguez, L. C","Lambarey, H.","Chetram, A.","Riou, C.","Wilkinson, R. J","Joyimbana, W.","Jennings, L.","Orrell, C.","Jaramillo-Hernández, D. A","Schäfer, G."],"bibdata":{"bibtype":"article","type":"article","abstract":"Background: Globally, the most significant risk factors for adverse COVID-19 outcome are increasing age and cardiometabolic comorbidities. However, underlying coinfections may modulate COVID-19 morbidity and mortality, particularly in regions with high prevalence of infectious diseases. Methods: We retrospectively analyzed serum samples for IgG antibodies against the common circulating coronaviruses HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1 from non-hospitalized and hospitalized confirmed COVID-19 patients recruited during the first (June-August 2020) and second (October 2020-June 2021) COVID-19 wave in Cape Town, South Africa. Patients were grouped according to COVID-19 disease severity: Group 1: previously SARS-CoV-2 infected with positive serology and no symptoms (n=94); Group 2: acutely SARS-CoV-2 infected, hospitalized for COVID-19 and severe symptoms (n=92). Results: The overall anti-HCoV IgG seroprevalence in the entire patient cohort was 60.8% (95% CI: 53.7 – 67.8), with 37.1% HCoV-NL63 (95% CI: 30 – 44), 30.6% HCoV-229E (95% CI: 24 – 37.3), 22.6% HCoV-HKU1 (95% CI: 16.6 – 28.6), and 21.0% HCoV-OC43 (95% CI: 15.1 – 26.8). We observed a significantly higher overall HCoV presence (72.3% versus 48.9%) and coinfection frequency (43.6% versus 19.6%) in group 1 compared to group 2 patients with significantly higher presentation of HCoV-NL63 (67.0% versus 6.6%) and HCoV-HKU1 (31.1% versus 14.1%). However, only antibody titers for HCoV-NL63 were significantly higher in group 1 compared to group 2 patients (p \\textless 0.0001, 1.90 [95% CI: 0.62 – 2.45] versus 1.32 [95% CI: 0.30 – 2.01]) which was independent of the participants' HIV status. Logistic regression analysis revealed significantly protective effects by previous exposure to HCoV-NL63 [p \\textless 0.001, adjusted OR = 0.0176 (95% CI: 0.0039 – 0.0786)], while previous HCoV-229E exposure was associated with increased COVID-19 severity [p = 0.0051, adjusted OR = 7.3239 (95% CI: 1.8195–29.4800)]. Conclusion: We conclude that previous exposure to multiple common coronaviruses, and particularly HCoV-NL63, might protect against severe COVID-19, while no previous HCoV exposure or single infection with HCoV-229E might enhance the risk for severe COVID-19. To our knowledge, this is the first report on HCoV seroprevalence in South Africa and its possible association with cross-protection against COVID-19 severity.","author":[{"propositions":[],"lastnames":["Lesmes-Rodríguez"],"firstnames":["Lida","C"],"suffixes":[]},{"propositions":[],"lastnames":["Lambarey"],"firstnames":["Humaira"],"suffixes":[]},{"propositions":[],"lastnames":["Chetram"],"firstnames":["Abeen"],"suffixes":[]},{"propositions":[],"lastnames":["Riou"],"firstnames":["Catherine"],"suffixes":[]},{"propositions":[],"lastnames":["Wilkinson"],"firstnames":["Robert","J"],"suffixes":[]},{"propositions":[],"lastnames":["Joyimbana"],"firstnames":["Wendy"],"suffixes":[]},{"propositions":[],"lastnames":["Jennings"],"firstnames":["Lauren"],"suffixes":[]},{"propositions":[],"lastnames":["Orrell"],"firstnames":["Catherine"],"suffixes":[]},{"propositions":[],"lastnames":["Jaramillo-Hernández"],"firstnames":["Dumar","A"],"suffixes":[]},{"propositions":[],"lastnames":["Schäfer"],"firstnames":["Georgia"],"suffixes":[]}],"doi":"10.3389/FVIRO.2023.1125448/BIBTEX","issn":"2673818X","journal":"Frontiers in Virology","keywords":"COVID-19,HCoV-229E,HCoV-HKU1,HCoV-NL63,HCoV-OC43,OA,SARS-CoV-2,Serology,fund_ack,genomics_fund_ack,original","mendeley-tags":"OA,fund_ack,genomics_fund_ack,original","month":"feb","pages":"1125448","publisher":"Frontiers Media SA","title":"Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa","volume":"3","year":"2023","bibtex":"@article{Lesmes-Rodriguez2023,\r\nabstract = {Background: Globally, the most significant risk factors for adverse COVID-19 outcome are increasing age and cardiometabolic comorbidities. However, underlying coinfections may modulate COVID-19 morbidity and mortality, particularly in regions with high prevalence of infectious diseases. Methods: We retrospectively analyzed serum samples for IgG antibodies against the common circulating coronaviruses HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1 from non-hospitalized and hospitalized confirmed COVID-19 patients recruited during the first (June-August 2020) and second (October 2020-June 2021) COVID-19 wave in Cape Town, South Africa. Patients were grouped according to COVID-19 disease severity: Group 1: previously SARS-CoV-2 infected with positive serology and no symptoms (n=94); Group 2: acutely SARS-CoV-2 infected, hospitalized for COVID-19 and severe symptoms (n=92). Results: The overall anti-HCoV IgG seroprevalence in the entire patient cohort was 60.8{\\%} (95{\\%} CI: 53.7 – 67.8), with 37.1{\\%} HCoV-NL63 (95{\\%} CI: 30 – 44), 30.6{\\%} HCoV-229E (95{\\%} CI: 24 – 37.3), 22.6{\\%} HCoV-HKU1 (95{\\%} CI: 16.6 – 28.6), and 21.0{\\%} HCoV-OC43 (95{\\%} CI: 15.1 – 26.8). We observed a significantly higher overall HCoV presence (72.3{\\%} versus 48.9{\\%}) and coinfection frequency (43.6{\\%} versus 19.6{\\%}) in group 1 compared to group 2 patients with significantly higher presentation of HCoV-NL63 (67.0{\\%} versus 6.6{\\%}) and HCoV-HKU1 (31.1{\\%} versus 14.1{\\%}). However, only antibody titers for HCoV-NL63 were significantly higher in group 1 compared to group 2 patients (p {\\textless} 0.0001, 1.90 [95{\\%} CI: 0.62 – 2.45] versus 1.32 [95{\\%} CI: 0.30 – 2.01]) which was independent of the participants' HIV status. Logistic regression analysis revealed significantly protective effects by previous exposure to HCoV-NL63 [p {\\textless} 0.001, adjusted OR = 0.0176 (95{\\%} CI: 0.0039 – 0.0786)], while previous HCoV-229E exposure was associated with increased COVID-19 severity [p = 0.0051, adjusted OR = 7.3239 (95{\\%} CI: 1.8195–29.4800)]. Conclusion: We conclude that previous exposure to multiple common coronaviruses, and particularly HCoV-NL63, might protect against severe COVID-19, while no previous HCoV exposure or single infection with HCoV-229E might enhance the risk for severe COVID-19. To our knowledge, this is the first report on HCoV seroprevalence in South Africa and its possible association with cross-protection against COVID-19 severity.},\r\nauthor = {Lesmes-Rodr{\\'{i}}guez, Lida C and Lambarey, Humaira and Chetram, Abeen and Riou, Catherine and Wilkinson, Robert J and Joyimbana, Wendy and Jennings, Lauren and Orrell, Catherine and Jaramillo-Hern{\\'{a}}ndez, Dumar A and Sch{\\\"{a}}fer, Georgia},\r\ndoi = {10.3389/FVIRO.2023.1125448/BIBTEX},\r\nissn = {2673818X},\r\njournal = {Frontiers in Virology},\r\nkeywords = {COVID-19,HCoV-229E,HCoV-HKU1,HCoV-NL63,HCoV-OC43,OA,SARS-CoV-2,Serology,fund{\\_}ack,genomics{\\_}fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,genomics{\\_}fund{\\_}ack,original},\r\nmonth = {feb},\r\npages = {1125448},\r\npublisher = {Frontiers Media SA},\r\ntitle = {{Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa}},\r\nvolume = {3},\r\nyear = {2023}\r\n}\r\n","author_short":["Lesmes-Rodríguez, L. C","Lambarey, H.","Chetram, A.","Riou, C.","Wilkinson, R. J","Joyimbana, W.","Jennings, L.","Orrell, C.","Jaramillo-Hernández, D. A","Schäfer, G."],"key":"Lesmes-Rodriguez2023","id":"Lesmes-Rodriguez2023","bibbaseid":"lesmesrodriguez-lambarey-chetram-riou-wilkinson-joyimbana-jennings-orrell-etal-previousexposuretocommoncoronavirushcovnl63isassociatedwithreducedcovid19severityinpatientsfromcapetownsouthafrica-2023","role":"author","urls":{},"keyword":["COVID-19","HCoV-229E","HCoV-HKU1","HCoV-NL63","HCoV-OC43","OA","SARS-CoV-2","Serology","fund_ack","genomics_fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","y6ojaHcuarkmc4yRQ"],"keywords":["covid-19","hcov-229e","hcov-hku1","hcov-nl63","hcov-oc43","oa","sars-cov-2","serology","fund_ack","genomics_fund_ack","original"],"search_terms":["previous","exposure","common","coronavirus","hcov","nl63","associated","reduced","covid","severity","patients","cape","town","south","africa","lesmes-rodríguez","lambarey","chetram","riou","wilkinson","joyimbana","jennings","orrell","jaramillo-hernández","schäfer"],"title":"Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa","year":2023}